AMOEBA (EPA:ALMIB) - AMOEBA: Evolution of the composition of the Board of Directors of AMOEBA

Transparency directive : regulatory news

24/06/2021 17:45

PRESS RELEASE

Evolution of the composition of the Board of Directors of AMOEBA

Chassieu (France), June 24, 2021 - 5:45 p.m. - AMOÉBA (FR0011051598 - ALMIB),
producer of a biological biocide capable of eliminating bacterial risk in water
and human wounds, and of a biocontrol product for plant protection, still in
the development phase, announces the provisional appointment of Mr. Philippe
Dujardin as an independent director of the Board of Directors, to replace Mr
Pascal Reber for the remainder of his predecessor's term of office, i.e. until
the Ordinary General Meeting called to approve the financial statements for the
year ending 31 December 2022, subject to ratification by the next Ordinary
General Meeting.

After examining the situation of Mr Philippe Dujardin with regard to the
independence criteria defined by the MiddleNext Code to which AMOEBA refers,
the Board of Directors qualified Mr Philippe Dujardin as an independent
director.

Philippe DUJARDIN

Philippe Dujardin has 30 years of experience in growth companies. Previously
Deputy CEO of Awabot, Chief Financial Officer of Erytech Pharma, he was also
Director of Financing and Investor Relations at Infogrames / Atari Group.
He joined BOOSTHEAT in 2014 as C.F.O and held the positions of Head of
Development of BOOSTHEAT SA (partnerships, offers, international
development...) and Chief Executive Officer of BOOSTHEAT France.
Philippe Dujardin is a graduate of the Ecole Supérieure de Commerce de Reims
and of the Institut d'Etudes Politiques de Lyon.

Mr Pascal Reber will continue to bring his extensive experience and expertise
to the service of the Company and will attend future meetings of the Board of
Directors in a consultative role as censor.

"I welcome Philippe Dujardin to our Board of Directors. I am delighted with his
arrival, which reinforces the good governance of the Company and complements
the skills already present on the Board by bringing his solid financial
expertise and his experience in the management of innovative companies. I would
like to thank Pascal Reber for his support and involvement in the development
of the company over the past 7 years", says Fabrice Plasson, Chairman and CEO
of Amoeba.

About AMOEBA:
Amoéba's ambition is to become a major player in the treatment of bacterial
risk in the fields of water, healthcare and plant protection. Our biological
solution is an alternative to chemical products widely used today. Amoéba is
currently focusing on the market of industrial cooling towers estimated at
EUR1.7Bn (1) on a global chemical biocide market for water treatment, evaluated
at EUR21Bn (2) and on the biocontrol market for plant protection estimated
globally at EUR1.6Bn (4). In the future, the Company is looking at developing
new applications such as chronic wound care, estimated at EUR 751 million (3)
in the USA. Sales of associated products with healthcare, biocides and crop
protection are subject to the Company being granted local regulatory market
authorizations. The Company is currently in a trial phase for biocidal and
plant protection applications and does not market any products.
Created in 2010, based in Chassieu (Lyon, France) with a subsidiary in Canada
and in the United States, Amoéba is quoted on Euronext Growth. The Company is
a member of the BPIfrance Excellence network and is eligible for the PEA-PME
SME equity savings plan setup. More information on www.amoeba-nature.com.

(1) : Amoéba data combined from sources: DRIRE 2013, Eurostat, ARHIA 2013
(2) : Sources combined by Amoéba from water treaters, Freedonia, Eurostat et
MarketsandMarkets
(3): BCC Research, "Markets for Advanced Wound Management Technologies,"
Wellesley, MA, 2017
(4): Biopesticides Worldwide Market 2013, CPL, Wallingford, UK

Contacts:

Amoéba
Valérie FILIATRE
Directeur Général Adjoint
+33 4 26 69 16 00
v.filiatre@amoeba-nature.com

Calyptus
Relations investisseurs & Presse
Grégory BOSSON / Mathieu CALLEUX
+33 1 53 65 37 90 /91
amoeba@calyptus.net

Adresse : 38 Avenue des Frères Montgolfier, 69680 CHASSIEU
Société Anonyme au capital de 341 109,20 EUR
RCS Lyon 523 877 215

Tel: +33 (0)4 26 69 16 00 ? Email: contact@amoeba-nature.com
Linkedin: @amoeba-nature ? Twitter: @AmoebaNature
www.amoeba-nature.com

AMOEBA's latest news

02/05/2024 18:00

AMOEBA (EPA:ALMIB) - AMOEBA: Evolution of the composition of the Board of Directors of AMOEBA

Transparency directive : regulatory news

AMOEBA's latest news

Other stories